{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:43:52Z","timestamp":1790725432192,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00397681"],"award-info":[{"award-number":["RS-2024-00397681"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-00523575"],"award-info":[{"award-number":["RS-2025-00523575"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-00523575"],"award-info":[{"award-number":["RS-2025-00523575"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Growth differentiation factor-15 (GDF15), a stress-responsive cytokine of the transforming growth factor-\u03b2 superfamily, is elevated in cancer cachexia, chemotherapy-induced nausea, and hyperemesis gravidarum, making it both a biomarker and a therapeutic target. Here, we developed high-affinity GDF15 binders using an artificial intelligence-driven protein design framework. To achieve this, we systematically explored three complementary scaffold-generation strategies: scaffold grafting, diffusion-based de novo design, and scaffold-search and grafting, identifying distinct advantages \u2014 scaffold grafting rapidly optimized receptor-derived motifs to sub-nanomolar affinity; de novo diffusion produced topologically novel binders; and scaffold-search and grafting enabled access to concave site B of GDF15 by repurposing evolutionary structural analogs from natural complexes. The designed GDF15 binders were translated into two functional modalities. First, a one-step, wash-free luminescent biosensor was created by coupling a de novo binder to split-luciferase fragments, enabling the rapid and sensitive quantification of GDF15. Second, the highest-affinity binder was engineered as an Fc-fusion decoy receptor, thereby effectively neutralizing GDF15 signaling in cell-based assays (IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u20097.2\u2009nM), demonstrating comparable in vitro potency to ponsegromab, a monoclonal antibody currently undergoing phase II clinical trials. Together, this work establishes a versatile artificial intelligence-driven binder design pipeline with broad potential for next-generation diagnostics and therapeutics in cancer cachexia and other GDF15-mediated diseases.\n                  <\/jats:p>","DOI":"10.1038\/s12276-026-01727-x","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:03:45Z","timestamp":1778231025000},"page":"1626-1641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["De novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics"],"prefix":"10.1038","volume":"58","author":[{"given":"Jinsook","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0005-4864","authenticated-orcid":false,"given":"Ryeongeun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5701-7602","authenticated-orcid":false,"given":"Sohyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0029-3643","authenticated-orcid":false,"given":"Ho Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"1727_CR1","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/jcmm.17725","volume":"27","author":"M Asrih","year":"2023","unstructured":"Asrih, M. et al. Overview of growth differentiation factor 15 in metabolic syndrome. J Cell Mol Med 27, 1157\u20131167 (2023).","journal-title":"J Cell Mol Med"},{"key":"1727_CR2","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3892\/ol.2023.14049","volume":"26","author":"TT Ling","year":"2023","unstructured":"Ling, T. T., Zhang, J., Ding, F. W. & Ma, L. L. Role of growth differentiation factor 15 in cancer cachexia (review). Oncol Lett 26, 462 (2023).","journal-title":"Oncol Lett"},{"key":"1727_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-3-7091-0643-3_12","volume":"65","author":"J Strelau","year":"2003","unstructured":"Strelau, J., Schober, A., Sullivan, A., Schilling, L. & Unsicker, K. Growth\/differentiation factor-15 (GDF-15), a novel member of the TGF-\u03b2 superfamily, promotes survival of lesioned mesencephalic dopaminergic neurons in vitro and in vivo and is induced in neurons following cortical lesioning. J Neural Transm Suppl 65, 197\u2013203 (2003).","journal-title":"J Neural Transm Suppl"},{"key":"1727_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cytogfr.2021.11.002","volume":"64","author":"JA Siddiqui","year":"2022","unstructured":"Siddiqui, J. A. et al. Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia. Cytokine Growth Factor Rev 64, 71\u201383 (2022).","journal-title":"Cytokine Growth Factor Rev"},{"key":"1727_CR5","doi-asserted-by":"publisher","first-page":"e00249","DOI":"10.1128\/MCB.00249-18","volume":"38","author":"JJ Li","year":"2018","unstructured":"Li, J. J. et al. Growth differentiation factor 15 maturation requires proteolytic cleavage by PCSK3, -5, and -6. Mol Cell Biol 38, e00249\u201318 (2018).","journal-title":"Mol Cell Biol"},{"key":"1727_CR6","doi-asserted-by":"publisher","first-page":"116809","DOI":"10.1016\/j.biopha.2024.116809","volume":"176","author":"J Li","year":"2024","unstructured":"Li, J. et al. Overview of growth differentiation factor 15 (GDF15) in metabolic diseases. Biomed Pharmacother 176, 116809 (2024).","journal-title":"Biomed Pharmacother"},{"key":"1727_CR7","doi-asserted-by":"publisher","first-page":"e70251","DOI":"10.1111\/jcmm.70251","volume":"28","author":"JC Zhang","year":"2024","unstructured":"Zhang, J. C., Sun, J. Q., Li, J. L. & Xia, H. W. Targeting the GDF15 signalling for obesity treatment: recent advances and emerging challenges. J Cell Mol Med 28, e70251 (2024).","journal-title":"J Cell Mol Med"},{"key":"1727_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cmet.2018.07.018","volume":"28","author":"VWW Tsai","year":"2018","unstructured":"Tsai, V. W. W., Husaini, Y., Sainsbury, A., Brown, D. A. & Breit, S. N. The MIC-1\/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab 28, 353\u2013368 (2018).","journal-title":"Cell Metab"},{"key":"1727_CR9","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/nm.4392","volume":"23","author":"SE Mullican","year":"2017","unstructured":"Mullican, S. E. et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med 23, 1150 (2017).","journal-title":"Nat Med"},{"key":"1727_CR10","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/nm.4394","volume":"23","author":"LD Yang","year":"2017","unstructured":"Yang, L. D. et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med 23, 1158 (2017).","journal-title":"Nat Med"},{"key":"1727_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cmet.2018.12.016","volume":"29","author":"S Patel","year":"2019","unstructured":"Patel, S. et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab 29, 707 (2019).","journal-title":"Cell Metab"},{"key":"1727_CR12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.tem.2018.05.002","volume":"29","author":"SE Mullican","year":"2018","unstructured":"Mullican, S. E. & Rangwala, S. M. Uniting GDF15 and GFRAL: therapeutic opportunities in obesity and beyond. Trends Endocrinol Metab 29, 560\u2013570 (2018).","journal-title":"Trends Endocrinol Metab"},{"key":"1727_CR13","doi-asserted-by":"publisher","first-page":"e0133362","DOI":"10.1371\/journal.pone.0133362","volume":"10","author":"VW Tsai","year":"2015","unstructured":"Tsai, V. W. et al. Serum levels of human MIC-1\/GDF15 vary in a diurnal pattern, do not display a profile suggestive of a satiety factor and are related to BMI. PLoS ONE 10, e0133362 (2015).","journal-title":"PLoS ONE"},{"key":"1727_CR14","doi-asserted-by":"publisher","first-page":"490842","DOI":"10.1155\/2015\/490842","volume":"2015","author":"R Adela","year":"2015","unstructured":"Adela, R. & Banerjee, S. K. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res 2015, 490842 (2015).","journal-title":"J Diabetes Res"},{"key":"1727_CR15","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/cells11071073","volume":"11","author":"B Albuquerque","year":"2022","unstructured":"Albuquerque, B. et al. Neutralization of GDF15 prevents anorexia and weight loss in the monocrotaline-induced cardiac cachexia rat model. Cells 11, 876 (2022).","journal-title":"Cells"},{"key":"1727_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cmet.2019.12.004","volume":"31","author":"T Borner","year":"2020","unstructured":"Borner, T. et al. GDF15 induces anorexia through nausea and emesis. Cell Metab 31, 351 (2020).","journal-title":"Cell Metab"},{"key":"1727_CR17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.cmet.2020.10.023","volume":"32","author":"DM Breen","year":"2020","unstructured":"Breen, D. M. et al. GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates. Cell Metab 32, 1049\u20131063.e4 (2020).","journal-title":"Cell Metab"},{"key":"1727_CR18","doi-asserted-by":"publisher","first-page":"e0300443","DOI":"10.1371\/journal.pone.0309394","volume":"19","author":"JY Xiong","year":"2024","unstructured":"Xiong, J. Y. et al. Neutralizing antibody against GDF15 for treatment of cancer-associated cachexia. PLoS ONE 19, e0300443 (2024).","journal-title":"PLoS ONE"},{"key":"1727_CR19","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.2147\/CMAR.S261585","volume":"12","author":"J Ni","year":"2020","unstructured":"Ni, J. & Zhang, L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Manag Res 12, 5597\u20135605 (2020).","journal-title":"Cancer Manag Res"},{"key":"1727_CR20","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/jcsm.13435","volume":"15","author":"JD Groarke","year":"2024","unstructured":"Groarke, J. D. et al. Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design. J Cachexia Sarcopenia Muscle 15, 1054\u20131061 (2024).","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1727_CR21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41591-020-0945-x","volume":"26","author":"R Suriben","year":"2020","unstructured":"Suriben, R. et al. Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice. Nat Med 26, 1264 (2020).","journal-title":"Nat Med"},{"key":"1727_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.CCR-23-1631","volume":"30","author":"J Crawford","year":"2024","unstructured":"Crawford, J. et al. A phase Ib first-in-patient study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of ponsegromab in participants with cancer and cachexia. Clin Cancer Res 30, 489\u2013497 (2024).","journal-title":"Clin Cancer Res"},{"key":"1727_CR23","doi-asserted-by":"publisher","first-page":"e47650","DOI":"10.7554\/eLife.47650","volume":"8","author":"J Li","year":"2019","unstructured":"Li, J. et al. Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands. eLife 8, e47650 (2019).","journal-title":"eLife"},{"key":"1727_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"1727_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jmb.2010.11.008","volume":"405","author":"MD Tyka","year":"2011","unstructured":"Tyka, M. D. et al. Alternate states of proteins revealed by detailed energy landscape mapping. J Mol Biol 405, 607\u2013618 (2011).","journal-title":"J Mol Biol"},{"key":"1727_CR26","doi-asserted-by":"publisher","first-page":"W210","DOI":"10.1093\/nar\/gkac387","volume":"50","author":"L Holm","year":"2022","unstructured":"Holm, L. DALI server: structural unification of protein families. Nucleic Acids Res 50, W210\u2013W215 (2022).","journal-title":"Nucleic Acids Res"},{"key":"1727_CR27","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.adp1779","volume":"386","author":"M Gl\u00f6gl","year":"2024","unstructured":"Gl\u00f6gl, M. et al. Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists. Science 386, 1154\u20131161 (2024).","journal-title":"Science"},{"key":"1727_CR28","first-page":"845","volume":"626","author":"SV Torres","year":"2024","unstructured":"Torres, S. V. et al. De novo design of high-affinity binders of bioactive helical peptides. Nature 626, 845\u2013852 (2024).","journal-title":"Nature"},{"key":"1727_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87959-5","volume":"11","author":"E Fung","year":"2021","unstructured":"Fung, E. et al. Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation. Sci Rep 11, 3071 (2021).","journal-title":"Sci Rep"},{"key":"1727_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.add2187","volume":"378","author":"J Dauparas","year":"2022","unstructured":"Dauparas, J. et al. Robust deep learning-based protein sequence design using ProteinMPNN. Science 378, 49\u201355 (2022).","journal-title":"Science"},{"key":"1727_CR31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41392-023-01615-0","volume":"8","author":"ZY Yang","year":"2023","unstructured":"Yang, Z. Y., Zeng, X. X., Zhao, Y. & Chen, R. S. AlphaFold2 and its applications in the fields of biology and medicine. Signal Transduct Target Ther 8, 347 (2023).","journal-title":"Signal Transduct Target Ther"},{"key":"1727_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.devcel.2005.09.008","volume":"9","author":"TB Thompson","year":"2005","unstructured":"Thompson, T. B., Lerch, T. F., Cook, R. W., Woodruff, T. K. & Jardetzky, T. S. The structure of the Follistatin:Activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell 9, 535\u2013543 (2005).","journal-title":"Dev Cell"},{"key":"1727_CR33","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.1501303112","volume":"112","author":"LZ Mi","year":"2015","unstructured":"Mi, L. Z. et al. Structure of bone morphogenetic protein 9 procomplex. Proc Natl Acad Sci USA 112, 3710\u20133715 (2015).","journal-title":"Proc Natl Acad Sci USA"},{"key":"1727_CR34","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nsmb.3016","volume":"22","author":"EG Healey","year":"2015","unstructured":"Healey, E. G. et al. Repulsive guidance molecule is a structural bridge between neogenin and bone morphogenetic protein. Nat Struct Mol Biol 22, 458\u2013465 (2015).","journal-title":"Nat Struct Mol Biol"},{"key":"1727_CR35","doi-asserted-by":"publisher","first-page":"20251","DOI":"10.1073\/pnas.0807200106","volume":"105","author":"C Gr\u00fctter","year":"2008","unstructured":"Gr\u00fctter, C. et al. A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions. Proc Natl Acad Sci USA 105, 20251\u201320256 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"1727_CR36","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/75903","volume":"7","author":"T Kirsch","year":"2000","unstructured":"Kirsch, T., Sebald, W. & Dreyer, M. K. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol 7, 492\u2013496 (2000).","journal-title":"Nat Struct Biol"},{"key":"1727_CR37","doi-asserted-by":"publisher","first-page":"7632","DOI":"10.1021\/jacs.2c04192","volume":"144","author":"M Ravalin","year":"2022","unstructured":"Ravalin, M. et al. A single-component luminescent biosensor for the SARS-CoV-2 spike protein. J Am Chem Soc 144, 7632\u20137643 (2022).","journal-title":"J Am Chem Soc"},{"key":"1727_CR38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41592-020-0848-2","volume":"17","author":"JK Leman","year":"2020","unstructured":"Leman, J. K. et al. Macromolecular modeling and design in Rosetta: recent methods and frameworks. Nat Methods 17, 665\u2013680 (2020).","journal-title":"Nat Methods"},{"key":"1727_CR39","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41586-022-04654-9","volume":"605","author":"LX Cao","year":"2022","unstructured":"Cao, L. X. et al. Design of protein-binding proteins from the target structure alone. Nature 605, 551\u2013560 (2022).","journal-title":"Nature"},{"key":"1727_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38328-5","volume":"14","author":"NR Bennett","year":"2023","unstructured":"Bennett, N. R. et al. Improving de novo protein binder design with deep learning. Nat Commun 14, 2178 (2023).","journal-title":"Nat Commun"},{"key":"1727_CR41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41592-025-02626-1","volume":"22","author":"J Dauparas","year":"2025","unstructured":"Dauparas, J. et al. Atomic context-conditioned protein sequence design using LigandMPNN. Nat Methods 22, 215\u2013224 (2025).","journal-title":"Nat Methods"},{"key":"1727_CR42","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"1727_CR43","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089\u20131100 (2023).","journal-title":"Nature"},{"key":"1727_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57192-z","volume":"16","author":"W Yang","year":"2025","unstructured":"Yang, W. et al. Design of high-affinity binders to immune modulating receptors for cancer immunotherapy. Nat Commun 16, 2001 (2025).","journal-title":"Nat Commun"},{"key":"1727_CR45","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41586-024-08435-4","volume":"639","author":"A Marchand","year":"2025","unstructured":"Marchand, A. et al. Targeting protein\u2013ligand neosurfaces with a generalizable deep learning tool. Nature 639, 322\u2013331 (2025).","journal-title":"Nature"},{"key":"1727_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41586-025-09721-5","volume":"649","author":"NR Bennett","year":"2026","unstructured":"Bennett, N. R. et al. Atomically accurate de novo design of antibodies with RFdiffusion. Nature 649, 183\u2013193 (2026).","journal-title":"Nature"},{"key":"1727_CR47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/jcsm.12077","volume":"7","author":"L Lerner","year":"2016","unstructured":"Lerner, L. et al. MAP3K11\/GDF15 axis is a critical driver of cancer cachexia. J Cachexia Sarcopenia Muscle 7, 467\u2013482 (2016).","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1727_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-023-06921-9","volume":"625","author":"M Fejzo","year":"2024","unstructured":"Fejzo, M. et al. GDF15 linked to maternal risk of nausea and vomiting during pregnancy. Nature 625, 116\u2013123 (2024).","journal-title":"Nature"},{"key":"1727_CR49","first-page":"495","volume":"7","author":"M Thomas","year":"2013","unstructured":"Thomas, M., Mousa, S. S. & Mousa, S. A. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol 7, 495\u2013500 (2013).","journal-title":"Clin Ophthalmol"},{"key":"1727_CR50","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","volume":"151","author":"KM Mohler","year":"1993","unstructured":"Mohler, K. M. et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151, 1548\u20131561 (1993).","journal-title":"J Immunol"},{"key":"1727_CR51","doi-asserted-by":"publisher","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"LW Moreland","year":"1999","unstructured":"Moreland, L. W. et al. Etanercept therapy in rheumatoid arthritis \u2014 a randomized, controlled trial. Ann Intern Med 130, 478 (1999).","journal-title":"Ann Intern Med"},{"key":"1727_CR52","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14760584.2017.1306441","volume":"16","author":"S Scheiblhofer","year":"2017","unstructured":"Scheiblhofer, S., Laimer, J., Machado, Y., Weiss, R. & Thalhamer, J. Influence of protein fold stability on immunogenicity and its implications for vaccine design. Exp Rev Vaccines 16, 479\u2013489 (2017).","journal-title":"Exp Rev Vaccines"},{"key":"1727_CR53","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.tibs.2019.12.008","volume":"45","author":"ZR Crook","year":"2020","unstructured":"Crook, Z. R., Nairn, N. W. & Olson, J. M. Miniproteins as a powerful modality in drug development. Trends Biochem Sci 45, 332\u2013346 (2020).","journal-title":"Trends Biochem Sci"},{"key":"1727_CR54","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-024-02010-z","volume":"9","author":"N Asada","year":"2024","unstructured":"Asada, N., Krebs, C. F. & Panzer, U. Miniproteins may have a big impact: new therapeutics for autoimmune diseases and beyond. Signal Transduct Target Ther 9, 298 (2024).","journal-title":"Signal Transduct Target Ther"},{"key":"1727_CR55","doi-asserted-by":"publisher","first-page":"18.19.1","DOI":"10.1002\/cpim.12","volume":"114","author":"S Paul","year":"2016","unstructured":"Paul, S., Sidney, J., Sette, A. & Peters, B. TepiTool: a pipeline for computational prediction of T cell epitope candidates. Curr Protoc Immunol 114, 18.19.1\u201318.19.24 (2016).","journal-title":"Curr Protoc Immunol"},{"key":"1727_CR56","doi-asserted-by":"publisher","first-page":"e1007757","DOI":"10.1371\/journal.pcbi.1007757","volume":"16","author":"S Paul","year":"2020","unstructured":"Paul, S. et al. Benchmarking predictions of MHC class I restricted T cell epitopes in a comprehensively studied model system. PLoS Comput Biol 16, e1007757 (2020).","journal-title":"PLoS Comput Biol"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01727-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01727-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01727-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:42:15Z","timestamp":1780548135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01727-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1727"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01727-x","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Equal Contribution statement has been added.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}